A sponsor-focused overview of clinical trials in Croatia; including EU CTIS integration, HALMED regulation, Zagreb's university hospital network, strong per-capita trial density, and therapeutic strengths in oncology, neurology, and endocrinology.
Croatia is a compact EU clinical trial market with strong per-capita research activity and a strategic position at the edge of Central Europe and the Balkans. For sponsors, Croatia offers EU regulatory credibility, motivated investigators, and access to well organized hospital networks anchored by Zagreb.
Clinical trials are regulated by HALMED (Agencija za lijekove i medicinske proizvode), which hosts the national Central Ethics Committee (CEC). Both HALMED and the CEC must approve trials, with the Ministry of Health issuing final authorisation. Croatia has operated under full EU CTR/CTIS integration since joining the EU, giving sponsors the same regulatory pathway they would use in France or Germany. An import licence for investigational products takes approximately 15 working days, and overall trial initiation timelines run 3–4 months from site selection to first patient. Croatia has the highest number of clinical trials per capita in the Balkans; ahead of Serbia and significantly ahead of Bosnia.
Croatia's 3.9 million people are predominantly Croatian (~90%), with Serbian, Bosniak, and other smaller communities. The population is aging, with a significant burden of cardiovascular disease, oncological conditions, and mental health disorders; the three areas that have historically dominated Croatia's trial portfolio. Urban concentration in Zagreb (~1.5M in the metropolitan area) makes patient recruitment efficient, while secondary research hubs in Split, Rijeka, and Osijek extend reach into the Dalmatian coast, Kvarner Bay, and Slavonia regions.
Croatia's physicians are well trained and internationally oriented; many have completed postgraduate training in Austria, Germany, or other EU countries; bringing international GCP standards to their home practice. Investigator motivation is high, partly driven by access to clinical trial data and novel therapies that strengthen research careers within Croatia's competitive academic medical environment.
The per-capita benchmark: Despite its small population, Croatia has a higher clinical trial density per capita than Serbia and significantly higher than Bosnia; reflecting the quality of its regulatory environment, investigator community, and EU membership that makes it a natural inclusion in any Southeast European multi-country programme.
Croatia combines EU regulatory credibility with CEE cost levels, three medical schools, and Zagreb's proven commercial Phase II–IV hub status; making it a natural inclusion in Southeast European multi-country programmes.
Full EU CTR/CTIS integration; HALMED-hosted Central Ethics Committee; simultaneous HALMED and CEC review; 15 working-day IMP import licence; 3–4 month total initiation timeline; documentation requirements clear and transparent; English widely used by investigator teams.
EU-standard data quality at CEE cost levels; lower trial operating costs than Western Europe; well below Austria/Germany; competitive investigator fees; Zagreb's international connectivity (direct flights to most European capitals); EU membership eliminates non-EU regulatory overhead.
3.9M people; aging population with high CVD, oncology, and psychiatric disease burden; treatment-naïve patient pools; high physician recommendation rates; Zagreb's 1.5M metropolitan catchment enabling efficient single-city multi-site programmes; Split, Rijeka, Osijek extending national reach.
3 medical schools (Zagreb, Split, Rijeka); university hospital network across all 4 major cities; multilingual staff (Croatian, English, German); Zagreb proven commercial Phase II–IV hub; strong potential in Split, Rijeka, Osijek per feasibility analysis; GCP compliance since 2013 EU accession.
Oncology and mental and behavioural disorders lead Croatia's therapeutic mix, with strong endocrinology and cardiovascular activity, and a growing rare disease and medical device portfolio.
Zagreb anchors Croatian clinical research with its university hospital network, including KBC Zagreb and the dedicated oncology hospital Sestre milosrdnice. Rijeka, Split, and Osijek extend research capacity across the Adriatic coast and Slavonia.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | University Hospital Centre Zagreb (KBC Zagreb) | Zagreb | Croatia's largest and most research-active hospital; University of Zagreb Medical Faculty affiliate; broad Phase II–IV portfolio across oncology, cardiovascular, neurology, and rare diseases; national referral centre; anchor of Croatian commercial research. |
| 02 | University Hospital for Tumors (KBC Sestre milosrdnice) | Zagreb | Dedicated oncology university hospital; Phase II–IV solid tumour and hematologic malignancy trials; University of Zagreb affiliate; major commercial Phase III oncology portfolio; head and neck, breast, and colorectal cancer specialty. |
| 03 | University Hospital Centre Rijeka (KBC Rijeka) | Rijeka | Adriatic coast anchor; University of Rijeka Medical Faculty affiliate; oncology, cardiovascular, and neurology trials; access to Kvarner and Istria patient populations; Phase II–IV commercial portfolio; proven commercial research site. |
| 04 | University Hospital Centre Split (KBC Split) | Split | Dalmatian coast anchor; University of Split School of Medicine affiliate; oncology, cardiovascular, and endocrinology trials; access to Split-Dalmatia patient population; Phase II–IV commercial portfolio; growing research infrastructure. |
| 05 | University Hospital Osijek (KBC Osijek) | Osijek | Slavonia region anchor; Josip Juraj Strossmayer University Medical Faculty affiliate; oncology, cardiovascular, and endocrinology trials; access to Eastern Croatia patient population; Phase II–III commercial portfolio; proven commercial recruitment. |
| 06 | Clinical Hospital Dubrava | Zagreb | University of Zagreb affiliate; oncology, gastroenterology, and cardiovascular trials; Eastern Zagreb patient catchment; Phase II–III commercial portfolio; growing research infrastructure with efficient site management. |
| 07 | University Hospital Centre Osijek; Psychiatric Clinic | Osijek | Psychiatric specialty; Phase II–IV CNS and mental health trials; one of Croatia's leading psychiatric research centres; strong commercial Phase III portfolio for antipsychotics, antidepressants, and mood disorders. |
| 08 | Children's Hospital Zagreb (Klaićeva) | Zagreb | National paediatric hospital; paediatric oncology, rare disease, and infectious disease trials; Phase II–IV; University of Zagreb affiliate; access to Croatian paediatric patient population. |
| 09 | Institute of Rheumatology and Rehabilitation Mlinovi | Zagreb | Rheumatology and rehabilitation specialist; Phase II–IV rheumatology and autoimmune trials; large treatment-naïve rheumatoid arthritis and SpA patient pools; strong commercial Phase III biologics portfolio. |
| 10 | General Hospital Dr. Josip Benčević Slavonski Brod | Slavonski Brod | Posavina region hospital near Serbian border; oncology, cardiovascular, and metabolic trials; access to Brod-Posavina region patient population; Phase II–III commercial portfolio; growing research activity. |
Croatia's largest and most research-active hospital; University of Zagreb Medical Faculty affiliate; broad Phase II–IV portfolio across oncology, cardiovascular, neurology, and rare diseases; national referral centre; anchor of Croatian commercial research.
Dedicated oncology university hospital; Phase II–IV solid tumour and hematologic malignancy trials; University of Zagreb affiliate; major commercial Phase III oncology portfolio; head and neck, breast, and colorectal cancer specialty.
Adriatic coast anchor; University of Rijeka Medical Faculty affiliate; oncology, cardiovascular, and neurology trials; access to Kvarner and Istria patient populations; Phase II–IV commercial portfolio; proven commercial research site.
Dalmatian coast anchor; University of Split School of Medicine affiliate; oncology, cardiovascular, and endocrinology trials; access to Split-Dalmatia patient population; Phase II–IV commercial portfolio; growing research infrastructure.
Slavonia region anchor; Josip Juraj Strossmayer University Medical Faculty affiliate; oncology, cardiovascular, and endocrinology trials; access to Eastern Croatia patient population; Phase II–III commercial portfolio; proven commercial recruitment.
University of Zagreb affiliate; oncology, gastroenterology, and cardiovascular trials; Eastern Zagreb patient catchment; Phase II–III commercial portfolio; growing research infrastructure with efficient site management.
Psychiatric specialty; Phase II–IV CNS and mental health trials; one of Croatia's leading psychiatric research centres; strong commercial Phase III portfolio for antipsychotics, antidepressants, and mood disorders.
National paediatric hospital; paediatric oncology, rare disease, and infectious disease trials; Phase II–IV; University of Zagreb affiliate; access to Croatian paediatric patient population.
Rheumatology and rehabilitation specialist; Phase II–IV rheumatology and autoimmune trials; large treatment-naïve rheumatoid arthritis and SpA patient pools; strong commercial Phase III biologics portfolio.
Posavina region hospital near Serbian border; oncology, cardiovascular, and metabolic trials; access to Brod-Posavina region patient population; Phase II–III commercial portfolio; growing research activity.
These are the primary regulatory, academic, and industry bodies shaping Croatia's clinical research ecosystem.
National competent authority; hosts Central Ethics Committee (CEC); full EU CTR/CTIS integration; 15-working-day IMP import licence; simultaneous HALMED and CEC review; Ministry of Health issues final trial authorisation.
Croatia's leading medical school; affiliates KBC Zagreb, KBC Sestre milosrdnice, and Dubrava; drives investigator pipeline; GCP training; core of Croatian commercial research infrastructure.
Dalmatian coast medical school; KBC Split affiliate; growing research portfolio; Adriatic coast patient population access; international orientation through Mediterranean collaborations.
Global CRO with Zagreb operations; HALMED regulatory expertise; Phase II–IV management; national site networks across Zagreb, Split, Rijeka, and Osijek; integrates Croatia into SEE multi-country programmes.
Regional CRO with Croatian coverage; oncology, cardiology, and rare disease specialty; site management across Zagreb and regional centres; packages Croatia into broader CEE/SEE multi-country programmes.
For sponsors evaluating clinical trials in Croatia, the opportunity is defined by the country's regulatory pathway, investigator depth, patient access, and fit within a wider regional clinical research strategy. This profile is designed to support faster country feasibility, smarter site selection, and more informed clinical trial planning through Kitsa.
Croatia is the Balkans' most trial-active country per capita; and its EU membership since 2013 is the key differentiator from its non-EU Balkan neighbours. Full CTIS integration, a 3–4 month initiation timeline, HALMED's transparent regulatory process, three medical schools, and Zagreb's proven commercial research hub status combine to make Croatia a natural addition to any Southeast European multi-country programme. For sponsors running CEE packages that include Hungary and Romania, adding Croatia's 3.9 million EU-standard patients costs minimal additional regulatory effort and delivers measurable enrollment uplift; particularly in oncology, mental health, and endocrinology.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.